Tag: Ss 31

In a clinical trial for primary mitochondrial myopathy, patients reported statistically significant and clinically meaningful improvements in fatigue while on elamipretide (SS-31). Many who research this peptide wonder, 'How does SS-31 make you feel?' as its effects on energy, physical performance, and cognition are directly related to its mitochondrial-targeting mechanism.

Did you know that the synthetic peptide SS-31, also known as elamipretide, can accumulate within the mitochondria of cells at concentrations up to 5,000 times higher than in other cellular areas? This remarkable selectivity is key to understanding precisely what does SS 31 do, focusing its therapeutic effects on the cell's energy-producing powerhouse.

Following the FDA's accelerated approval in September 2025, elamipretide, now known as Forzinity, is the first approved treatment for Barth syndrome. Clinical trial data indicates that treatment duration for this chronic condition extends well beyond the initial study period, with some patients safely receiving the medication for several years.

Mitochondrial dysfunction is a central factor in many age-related diseases and overall decline, leading to reduced energy and increased cellular damage. SS-31 peptide, also known as Elamipretide, is a groundbreaking, mitochondria-targeting compound designed to specifically address this root cause by stabilizing and optimizing mitochondrial function.